ClinicalTrials.gg
Active, not recruitingNCT03377023Updated Apr 2, 2026Results posted

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

A Phase 1/2 interventional study of Nivolumab and Ipilimumab in Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell and Non Small Cell Lung Cancer Metastatic, sponsored by H. Lee Moffitt Cancer Center and Research Institute. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
60th of 120
66 · median 66
Started
2018
with 14 others
Phase 1/2
12 of 120
2 open now
Primary completion
2023-11
later than 3 of 43 live
Registered
59th of 120
by date
Lead sponsor
2 of 120
H. Lee Moffitt Cancer Center and Research Institute

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 60th largest by enrollment, is one of 15 that started in 2018, is one of 12 in phase 1/2, reaches primary completion later than 3 of the 43 other live ones, and was the 59th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main purpose of this study is to see if the combination of nivolumab, ipilimumab and nintedanib is effective in people with non- small cell lung cancer. Researchers also want to find out if the combination of nivolumab, ipilimumab and nintedanib is safe and tolerable.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Lung Cancer, Nonsmall Cell
  • Non Small Cell Lung Cancer Metastatic

Keywords

  • Nivolumab
  • Ipilimumab
  • Nintedanib
  • Immunotherapy
  • Advanced stage non-small cell lung cancer
  • Locally advanced non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have histologic or cytological diagnosis of advanced/ Non-Small Cell Lung Cancer (NSCLC) with no curative treatment options. For those with mixed histology, there must be a predominant histology.
  • 18 years of age or older on day of signing .
  • of at least 3-6 months.
  • (ECOG) performance status score 0 and 1
  • For phase I trial portion, treatment naïve or patients previously treated with chemotherapy, immunotherapy or targeted therapy for NSCLC are allowed. Patient who underwent curative intent chemotherapy and/radiation in the or adjuvant setting are allowed to enroll if tumor recurrence occurred greater than 6 months from completion of that therapy (and will be considered treatment naïve in the Stage IV setting). Patients with NSCLC tumor known to harbor a genomic aberration for which FDA approved treatment is available (i.e, non-resistant EGFR mutations, EGFR T790M mutation, ALK rearrangement, ROS rearrangement, BRAF V600E mutation) are allowed to enroll if they have received prior treatment with the FDA approved targeted therapy.
  • For phase II trial portion, Patients will be enrolled as two parallel cohorts:

    • A.) Arm A (treatment naïve): Patients who are newly diagnosed and treatment naïve. Patient who underwent curative intent chemotherapy and/radiation in the neoadjuvant or adjuvant setting are allowed to enroll if tumor recurrence occurred greater than 6 months from completion of therapy. Patients with NSCLC tumor known to harbor a genomic aberration for which FDA approved treatment is available (i.e, non-resistant EGFR mutations, EGFR T790M mutation, ALK rearrangement, ROS rearrangement, BRAF V600E mutation) are allowed to enroll if they have received prior treatment with the FDA approved targeted therapy.
    • B.) Arm B (Immunotherapy pre-treated group): Patients who have received prior immunotherapy. Patients who are primary to immunotherapy (i.e., Patients who were previously treated with immunotherapy and did not at least achieve stable disease on first imaging assessment on immunotherapy) or have relapsed disease (i.e., Patients that were treated with immunotherapy, achieved at least stable disease on first imaging assessment and subsequently developed disease progression or relapse). Patients with NSCLC tumor known to harbor a genomic aberration for which FDA approved treatment is available (i.e, non-resistant EGFR mutations, EGFR T790M mutation, ALK rearrangement, ROS rearrangement, BRAF V600E mutation) are allowed to enroll if they have received prior treatment with the FDA approved targeted therapy
  • At least one according to (RECIST) v1.1 criteria.
  • must be \<470 ms for males and \<480 ms for females.
  • Adequate normal organ and marrow function as defined below:

    • (ANC) >1.5 x 10\^9/L (> 1500 per mm\^3)
    • ≥ 9.0 g/dL
    • count ≥ 100 x 10\^9/L (>100,000 per mm\^3)
    • Total ≤ 1.5 X normal institutional limits. For patients with liver metastasis: total bilirubin must be within normal limits.
    • Proteinuria less than (CTCAE) grade 2 or greater
    • (Except patients with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL
    • (SGOT)/ALT(SGPT) ≤1.5 X institutional upper limit of norma ()l or ≤ 2.5 X ULN for patients with liver metastases. This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.
    • Serum creatinine CL ≤ 1.5 X ULN or > 45 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
  • Have where available.
  • In addition, patients enrolled on the clinical trial must be willing and able to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Patients for whom newly obtained samples cannot be provided may submit an archived specimen only upon agreement from the Sponsor.
  • Female participants of should have a negative urine or serum pregnancy within 72 hours before receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Ability to understand and willingness to provide written informed consent signed and dated prior to admission to the study in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines and to the local legislation.

Exclusion criteria

Exclusion Criteria:

  • Concurrent use of other anticancer agents including chemotherapy, targeted therapy, radiotherapy or immunotherapy not otherwise specified in the protocol.
  • Concurrent use of other drugs or treatment in another clinical trial with a non- FDA-approved medication within the past 4 weeks before start of therapy.
  • Chemo-, or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 2 weeks prior to treatment with the trial drug.
  • Radiotherapy (except for brain and extremities or stereotactic treatment) within the past 2 weeks prior to treatment with the trial drug.
  • In immunotherapy pretreated patients, any history of dose-limiting toxicity with prior immunotherapy agents, including grade 3/4 immune-related adverse events (irAEs); irreversible irAEs; Grade ≥3 irAEs that did not respond to rescue; or neurologic irAE with significant clinical sequelae.
  • Prior treatment with nintedanib (BIBF1120).
  • Known to nintedanib, nivolumab, ipilimumab, peanut or soy or any other trial drug, or their .
  • Any toxicity (> version 5 grade 3) from previous anti-cancer therapy that has not resolved to a Grade 1. Persistence of therapy related toxicity from previous chemo and/or radiotherapy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy, alopecia).
  • History of .
  • Radiotherapy to a target lesion within the past 3 months prior to baseline imaging unless that area has demonstrated progression.
  • Active (e.g., stable for \<2 weeks, symptomatic, no adequate previous treatment, requiring treatment with anti-convulsants); dexamethasone therapy will be allowed if administered as stable or decreasing dose for at least 3 weeks before randomization otherwise no steroids to exceed prednisone 10 mg/day prior to starting trial treatment. Symptomatic or uncontrolled central nervous system (CNS) .
  • Current or prior use of medication 7 days before the first dose of nivolumab or ipilimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. A brief course (≤28 days) of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non- conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted. Topical corticosteroids are permitted.
  • Active or prior documented autoimmune disease within the past 2 years. NOTE: Patients with vitiligo, Grave's disease, type I diabetes mellitus or residual hypothyroidism due to autoimmune condition only requiring hormone replacement, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
  • Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels.
  • Has known history of, or any evidence of active, non-infectious pneumonitis.
  • Therapeutic anticoagulation with drugs requiring monitoring (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or antiplatelet therapy (except for low-dose therapy with acetylsalicylic acid \< 325 mg per day.
  • Major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period.
  • History of clinically significant hemorrhagic or thromboembolic event in the past 6 months.
  • Known inherited predisposition to bleeding or thrombosis.
  • Significant cardiovascular diseases (i.e., uncontrolled hypertension, unstable angina, history of infarction within the past 3 months prior to start of study treatment, congestive heart failure > (NYHA) II, serious cardiac arrhythmia).
  • Coagulation parameters: International normalized ratio (INR) > 2, prothrombin time (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional .
  • History of another primary within the past 2 years except for:

    • Basal cell skin cancer
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ)
  • Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
  • Has known active (e.g., HBsAg reactive) or (e.g., HCV RNA [qualitative] is detected)
  • History of known active primary immunodeficiency
  • History of allogeneic organ transplant
  • Receipt of within 30 days prior to study entry or within 30 days of receiving study treatment.
  • Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
  • Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastrointestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study
  • Patients who are sexually active and unwilling to use a medically acceptable method of (e.g., such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males) for the duration specified during the trial and after end of active therapy
  • Pregnancy or breastfeeding female patients must have a negative pregnancy test (β-HCG test in urine or serum) prior to commencing study treatment
  • Psychological, familial, sociological, or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
  • Active alcohol or drug abuse
  • Significant weight loss (> 20% of Body Weight) within past 6 months prior to inclusion into the trial
  • History of active tuberculosis
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Phase 1 Nintedanib Dose Escalation 100-200 mg QD to BID

    Nivolumab + Ipilimumab + Nintedanib dose escalation. Participants were given the following: Nivolumab: 3 mg/kg IV Q2 weeks. Ipilimumab: 1 mg/kg Q6 weeks. Nintedanib Level -1: 100 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =100 mg). Nintedanib Level 0:150 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =150 mg) Nintedanib Level 1: 100 mg PO twice daily (BID) Days 2-28 (Daily dose = 200 mg). Nintedanib Level 2: 150 mg PO BID Days 1-14 (Daily dose = 300 mg). Nintedanib Level 3: 200 mg PO BID Days 1-14 (Daily dose = 400 mg).

    Drug: Nivolumab · Drug: Ipilimumab · Drug: Nintedanib

  • Active comparator
    Phase 2 - Arm A Nintedanib 100-200 mg BID Treatment-naïve

    Arm A: Treatment-naïve defined as newly diagnosed or treatment-naïve patients, with a target overall response rate (ORR) of 50%. Participants were given the following: Nivolumab + Ipilimumab + Nintedanib at RP2D. Nivolumab: Intravenous nivolumab every 2 weeks. Ipilimumab: Intravenous ipilimumab every 6 weeks. Nintedanib: Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.

    Drug: Nivolumab · Drug: Ipilimumab · Drug: Nintedanib

  • Active comparator
    Phase 2 - Arm B Nintedanib 100-200 mg BID Treatment Non-naïve

    Arm B: Treatment Non-naïve defined as patients who have been previously exposed to immunotherapy, such as anti-PD-1, anti-PD-L1 or anti-CTLA-4, with a target ORR of 20%. Participants were given the following: Nivolumab + Ipilimumab + Nintedanib at RP2D. Nivolumab: Intravenous nivolumab every 2 weeks. Ipilimumab: Intravenous ipilimumab every 6 weeks. Nintedanib: Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.

    Drug: Nivolumab · Drug: Ipilimumab · Drug: Nintedanib

Interventions

  • Intravenous nivolumab every 2 weeks.

    Also known as: Opdivo®

  • Intravenous ipilimumab every 6 weeks.

    Also known as: Yervoy®

  • Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.

    Also known as: Vargatef®, Ofev®, BIBF1120

06

What researchers measure

Primary outcomes

  1. Phase 1 - Maximum Tolerated Dose (MTD)

    Dose escalation to determine the MTD and Recommended Phase 2 Dose (RP2D) of concurrent administration of nivolumab, ipilimumab, and nintedanib. The maximum tolerated dose (MTD) is defined as the dose with the dose limiting toxicity (DLT) rate of 30%. Phase 1 began with 100 mg nintedanib, 3 mg/kg IV nivolumab + 1 mg/kg ipilimumab. Dosing of nintedanib increased by 50 mg in each level until dose limiting toxicity.

    Time frame: Up to 12 months

  2. Phase 2 - Objective Response Rate (ORR) Per Treatment Arm

    Objective response is defined as confirmed CR or confirmed PR based on modified RECIST guidelines version 1.1. The ORR will be estimated by calculating the proportion of patients who achieve OR; the 80% Confidence Interval (CI) and 95% CI for the OR rate will be estimated using the exact binomial distribution. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 36 months

Secondary outcomes

  1. Phase 2: Disease Control Rate (DCR)

    Disease control is defined as CR, PR, or SD based on RECIST guidelines version 1.1 with modifications. The disease control rate (DCR) will be estimated by the proportion of patients who achieve DC, and its 80% CI and 95% CI will be estimated using the exact binomial distribution. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Up to 36 months

  2. Phase 2: Overall Survival (OS)

    Overall survival will be determined as the time from the start of treatment with nivolumab plus ipilimumab plus nintedanib until death due to any cause. For patients who are alive at the time of data cut-off, OS will be censored on the last date when patients are known to be alive. This result is provided as number of months of survival.

    Time frame: Up to 36 months

  3. Phase 2: Progression-free Survival (PFS)

    Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

    Time frame: Up to 36 months

07

Results

Posted Mar 25, 2025

Participant flow

Participant flow — Overall Study
MilestonePhase 1 Nintedanib Level -1: 100 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 100 mg)Phase 1 Nintedanib Level 0: 150 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 150 mg)Phase 1 Nintedanib Level 1: 100 mg by Mouth (PO) Twice Daily (BID) Days 2-28 (Daily Dose 200 mg)Phase 2 - Arm A Nintedanib 200 mg BID Treatment-naïvePhase 2- Arm B Nintedanib 200 mg BID Treatment Non-naïve
Started3652230
Completed3652230
Not completed00000

Outcome measures

PrimaryPhase 1 - Maximum Tolerated Dose (MTD)

Dose escalation to determine the MTD and Recommended Phase 2 Dose (RP2D) of concurrent administration of nivolumab, ipilimumab, and nintedanib. The maximum tolerated dose (MTD) is defined as the dose with the dose limiting toxicity (DLT) rate of 30%. Phase 1 began with 100 mg nintedanib, 3 mg/kg IV nivolumab + 1 mg/kg ipilimumab. Dosing of nintedanib increased by 50 mg in each level until dose limiting toxicity.

Time frame:
Up to 12 months
Reported as:
Number · miligrams nintedanib
Phase 1 - Maximum Tolerated Dose (MTD)
miligrams nintedanibPhase 1-Dose Escalation
Phase 1 - Maximum Tolerated Dose (MTD)150
PrimaryPhase 2 - Objective Response Rate (ORR) Per Treatment Arm

Objective response is defined as confirmed CR or confirmed PR based on modified RECIST guidelines version 1.1. The ORR will be estimated by calculating the proportion of patients who achieve OR; the 80% Confidence Interval (CI) and 95% CI for the OR rate will be estimated using the exact binomial distribution. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 36 months
Reported as:
Number · percentage of participants
Phase 2 - Objective Response Rate (ORR) Per Treatment Arm
percentage of participantsPhase 2 - Arm APhase 2 - Arm B
Phase 2 - Objective Response Rate (ORR) Per Treatment Arm40.9 (21.5 to 63.3)21.4 (9.03 to 41.5)
SecondaryPhase 2: Disease Control Rate (DCR)

Disease control is defined as CR, PR, or SD based on RECIST guidelines version 1.1 with modifications. The disease control rate (DCR) will be estimated by the proportion of patients who achieve DC, and its 80% CI and 95% CI will be estimated using the exact binomial distribution. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Up to 36 months
Reported as:
Number · percentage of participants
Phase 2: Disease Control Rate (DCR)
percentage of participantsPhase 2 - Arm APhase 2 - Arm B
Phase 2: Disease Control Rate (DCR)72.7 (49.6 to 88.4)57.1 (37.4 to 75.0)
SecondaryPhase 2: Overall Survival (OS)

Overall survival will be determined as the time from the start of treatment with nivolumab plus ipilimumab plus nintedanib until death due to any cause. For patients who are alive at the time of data cut-off, OS will be censored on the last date when patients are known to be alive. This result is provided as number of months of survival.

Time frame:
Up to 36 months
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsPhase 2 - Arm APhase 2 - Arm B
Phase 2: Overall Survival (OS)17.1 (5.5 to 46.9)8.2 (5.0 to 25.3)
SecondaryPhase 2: Progression-free Survival (PFS)

Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Time frame:
Up to 36 months
Reported as:
Median · months
Phase 2: Progression-free Survival (PFS)
monthsPhase 2 - Arm APhase 2 - Arm B
Phase 2: Progression-free Survival (PFS)5.5 (2.9 to 36.0)2.6 (1.4 to 6.9)

Adverse events

Collected over Adverse Events were collected from start of Study Treatment to 100 days from end of treatment. Approximately 57 Months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 Nintedanib Level -1: 100 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 100 mg)3/3 (100%)1/3 (33.3%)3/3 (100%)
Phase 1 Nintedanib Level 0: 150 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 150 mg)4/6 (66.7%)4/6 (66.7%)6/6 (100%)
Phase 1 Nintedanib Level 1: 100 mg by Mouth (PO) Twice Daily (BID) Days 2-28 (Daily Dose 200 mg)5/5 (100%)4/5 (80%)5/5 (100%)
Phase 2- Arm A Nintedanib 200 mg BID Treatment-naïve19/22 (86.4%)14/22 (63.6%)22/22 (100%)
Phase 2- Arm B Nintedanib 200 mg BID Treatment Non-naïve23/30 (76.7%)15/30 (50%)29/30 (96.7%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventPhase 1 Nintedanib Level -1: 100 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 100 mg)Phase 1 Nintedanib Level 0: 150 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 150 mg)Phase 1 Nintedanib Level 1: 100 mg by Mouth (PO) Twice Daily (BID) Days 2-28 (Daily Dose 200 mg)Phase 2- Arm A Nintedanib 200 mg BID Treatment-naïvePhase 2- Arm B Nintedanib 200 mg BID Treatment Non-naïve
FractureInjury, poisoning and procedural complications1/30/60/50/220/30
Neoplasms benign, malignant and unspecified (incl cysts and polyps)-Other, specifyNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/61/51/222/30
VomitingGastrointestinal disorders0/31/61/51/222/30
DiarrheaGastrointestinal disorders0/30/61/51/221/30
Alanine aminotransferase increasedInvestigations0/30/61/50/220/30
Aspartate aminotransferase increasedInvestigations0/30/61/50/220/30
Rash maculo-papularSkin and subcutaneous tissue disorders0/30/61/50/220/30
Bone painMusculoskeletal and connective tissue disorders0/30/61/50/220/30
NauseaGastrointestinal disorders0/31/60/52/223/30
Adrenal insufficiencyEndocrine disorders0/31/60/51/221/30
Most frequent other events
Showing 10 of 202
Most frequent other events
EventPhase 1 Nintedanib Level -1: 100 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 100 mg)Phase 1 Nintedanib Level 0: 150 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 150 mg)Phase 1 Nintedanib Level 1: 100 mg by Mouth (PO) Twice Daily (BID) Days 2-28 (Daily Dose 200 mg)Phase 2- Arm A Nintedanib 200 mg BID Treatment-naïvePhase 2- Arm B Nintedanib 200 mg BID Treatment Non-naïve
FatigueGeneral disorders2/36/62/512/2216/30
DiarrheaGastrointestinal disorders0/35/61/514/2212/30
AnorexiaMetabolism and nutrition disorders1/34/62/59/2213/30
Investigations - Other, specifyInvestigations1/34/63/55/225/30
NauseaGastrointestinal disorders0/33/62/514/2216/30
DyspneaRespiratory, thoracic and mediastinal disorders1/32/63/55/228/30
Alanine aminotransferase increasedInvestigations1/33/63/54/227/30
Aspartate aminotransferase increasedInvestigations1/33/63/53/227/30
PainGeneral disorders1/33/60/56/223/30
VomitingGastrointestinal disorders0/33/61/53/229/30

Baseline characteristics

Evaluable Participants

Age, Categorical
Age, Categorical(Participants)Phase 1 Nintedanib Level -1: 100 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 100 mg)Phase 1 Nintedanib Level 0: 150 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 150 mg)Phase 1 Nintedanib Level 1: 100 mg by Mouth (PO) Twice Daily (BID) Days 2-28 (Daily Dose 200 mg)Phase 2- Arm A Nintedanib 200 mg BID Treatment-naïvePhase 2- Arm B Nintedanib 200 mg BID Treatment Non-naïveTotal
<=18 years000000
Between 18 and 65 years13391329
>=65 years232131535
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 Nintedanib Level -1: 100 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 100 mg)Phase 1 Nintedanib Level 0: 150 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 150 mg)Phase 1 Nintedanib Level 1: 100 mg by Mouth (PO) Twice Daily (BID) Days 2-28 (Daily Dose 200 mg)Phase 2- Arm A Nintedanib 200 mg BID Treatment-naïvePhase 2- Arm B Nintedanib 200 mg BID Treatment Non-naïveTotal
Female134121535
Male231101329
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1 Nintedanib Level -1: 100 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 100 mg)Phase 1 Nintedanib Level 0: 150 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 150 mg)Phase 1 Nintedanib Level 1: 100 mg by Mouth (PO) Twice Daily (BID) Days 2-28 (Daily Dose 200 mg)Phase 2- Arm A Nintedanib 200 mg BID Treatment-naïvePhase 2- Arm B Nintedanib 200 mg BID Treatment Non-naïveTotal
Hispanic or Latino100023
Not Hispanic or Latino265202558
Unknown or Not Reported000213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1 Nintedanib Level -1: 100 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 100 mg)Phase 1 Nintedanib Level 0: 150 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 150 mg)Phase 1 Nintedanib Level 1: 100 mg by Mouth (PO) Twice Daily (BID) Days 2-28 (Daily Dose 200 mg)Phase 2- Arm A Nintedanib 200 mg BID Treatment-naïvePhase 2- Arm B Nintedanib 200 mg BID Treatment Non-naïveTotal
American Indian or Alaska Native000000
Asian000011
Native Hawaiian or Other Pacific Islander000000
Black or African American000123
White365202357
More than one race000000
Unknown or Not Reported000123
Region of Enrollment
Region of Enrollment(participants)Phase 1 Nintedanib Level -1: 100 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 100 mg)Phase 1 Nintedanib Level 0: 150 mg by Mouth (PO) Once a Day (QD) Days 1-14 (Daily Dose 150 mg)Phase 1 Nintedanib Level 1: 100 mg by Mouth (PO) Twice Daily (BID) Days 2-28 (Daily Dose 200 mg)Phase 2- Arm A Nintedanib 200 mg BID Treatment-naïvePhase 2- Arm B Nintedanib 200 mg BID Treatment Non-naïveTotal
United States365222965
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Nov 2023, 69 months.

Results were first posted in Mar 2025, 1 year 3 months after primary completion.

Of 123 non-industry phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 107. This study's 69 months is close to that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Dec 19, 2017
StartActual
Feb 2, 2018
Primary completionActual
Nov 28, 2023
CompletionEst.
Aug 2026
Results first posted
Mar 25, 2025
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03377023
Responsible party
Sponsor
First posted
Dec 19, 2017
Start date
Feb 2, 2018
Primary completion
Nov 28, 2023
Completion
Aug 2026 (estimated)
Results posted
Mar 25, 2025
Last update
Apr 2, 2026

Study contacts

Jhanelle E. Gray, M.D.
principal investigator · H. Lee Moffitt Cancer Center and Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Nintedanib

Start the discussion